Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

Summary

Phase I study to evaluate the human safety and tolerability, biodistribution and dosimetry of 68GaNOTA-Anti-MMR-VHH2 Phase IIa study to evaluate tumour uptake of 68Ga-NOTA-anti-MMR-VHH2 in patients with breast cancer or melanoma. To correlate uptake of 68Ga-NOTA-anti-MMR-VHH2 in cancer lesions to immunohistological MMR staining after resection or biopsy of the same lesion.

Timeline

Start

2019-11-05

Primary completion

2024-12-04

Completion

2024-12-04

Outcome

Outcome not reported

Stopped (Enrollment): “Delay in recruitment”

Drugs

Indications